GH/PRL-secreting pituitary macroadenoma associated with GNASp.Gln227Leu mutation: pediatric case report and review

Daisuke Watanabe, Hideaki Yagasaki, Satoru Kojika, Masakazu Ogiwara, Hiroyuki Kinouchi, Takaya Nakane, Takeshi Inukai

Author information

Keywords: GH-secreting pituitary adenoma (GHoma), Octreotide long-acting release (LAR), Gigantism, Guanine nucleotide-binding protein alpha stimulating (GNAS), p.Gln227Leu

JOURNALS FREE ACCESS FULL-TEXT HTML

2019 Volume 66 Issue 5 Pages 403-408

DOI https://doi.org/10.1507/endocrj.EJ18-0370

Browse "Advance Publication" version.

Details

Full Text-HTML
Download PDF (1598K)

Download Meta
RIS

(compatible with EndNote, Reference Manager, ProCite, RefWorks)

BIB TEX

(compatible with BibDesk, LaTeX)

Text

How to download Meta

Contact us

Article overview

Abstract
References (32)
Figures (3)
Information related to the author
Share


Abstract

GH-secreting pituitary adenomas (GHomas) are rare in the pediatric population. Guanine nucleotide-binding protein, alpha stimulating (GNAS) somatic mutations are often found in patients with GHoma. Here, we report an 8-year-old girl with GH-secreting pituitary adenoma successfully treated by operative tumor resection and postoperative treatment with octreotide long-acting release (LAR). Tumor DNA sequence analysis revealed a somatic heterozygous c.680A>T (p.Gln227Leu) mutation in GNAS. We reviewed 1,084 cases of GHomas, 409 (37.7%) of which harbored GNAS mutations. In pediatrics cases, aged 15 years or younger, 11 harbored a GNAS mutation, and GNAS p.Arg201Cys was identified in five cases. No other cases of codon 227 mutation were detected. These cases suggest that, in pediatric patients, the clinical features of GHoma may differ from those observed in adults. This is possibly related to octreotide or dopamine agonist resistance. Of six patients with surgical resistance, only one was reactive when treated with octreotide. Our case shows that octreotide LAR is an effective choice for treating GNAS-induced GHoma. This is the first report detailing the effectiveness of octreotide LAR in a GNAS codon 227 mutation-induced GHoma in a pediatric case. Examination of the relationship between genetic variation and clinical features in pediatric patients will enable us to assess the long-term effects of surgical and medical treatment of GHomas.

References (32)

1 Matsumoto R, Izawa M, Fukuoka H, Iguchi G, Odake Y, et al. (2016) Genetic and clinical characteristics of Japanese patients with sporadic somatotropinoma. Endocr J 63: 953–963.

2 Rostomyan L, Daly AF, Petrossians P, Nachev E, Lila AR, et al. (2015) Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr Relat Cancer 22: 745–757.

3 Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, et al. (1898) GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340: 692–696.

4 Freda PU, Chung WK, Matsuoka N, Walsh JE, Kanibir MN, et al. (2007) Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission. Pituitary 10: 275–282.

5 Creo AL, Lteif AN (2016) Pituitary gigantism: a retrospective case series. J Pediatr Endocrinol Metab 29: 597–607.
View more
Figures (3)







Information related to the author